Silence Therapeutics PLC (SLN) News

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to...

Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming...

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

Curtis Rambaran, MD, promoted to Chief Medical Officer Marie Wikström Lindholm, PhD, promoted to Chief...

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

SLN124 phase 1/2 study in polycythemia vera progressing well – data expected in mid-2024 Zerlasiran multiple dose study in patients with high...

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming...

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Zerlasiran showed very significant and durable reductions in lipoprotein(a) of up to 99% Lp(a) levels remained around 90% lower than baseline at...

Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming...

Silence Therapeutics to Participate in September Investor Conferences

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming...

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Silence Therapeutics Reports Second Quarter 2023 Results

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...